Consider rifampin BUT be cautious

Chest

Volumn 130, Issue 6, 2006, Pages 1638-1640

  Ashkin, David ^a,b   Julien, Joanne ^a,b   Lauzardo, Michael ^a,b   Hollender, Elena ^a,b  

^a A G Holley State TB Hospital ^*

^b A G Holley State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANTIBIOTIC RESISTANCE; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; EDITORIAL; HUMAN; LATENT PERIOD; LIVER TOXICITY; PRIORITY JOURNAL; SIDE EFFECT; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 33845925971     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1638     Document Type: Editorial

References (10)

1. Kaufmann ST, Mittrûcker HW. Vaccination against tuberculosis: current status and future promise. Semin Respir Crit Care Med 2004; 3:345-352
2. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-S247
3. Nuerraberger E, Bishai WR, Grosset JH. Latent tuberculosis infection. Semin Respir Crit Care Med 2004; 3:317-336
4. International Union Against Tuberculosis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60:555-564
5. Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion with four months of rifampin. Chest 2006; 130:1712-1717
6. Menzies RI, Dion M, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170:445-449
7. Hong Kong Chest Service, Tuberculosis Research Centre, Madras and BMJ Research Council, 1992. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41
8. Corbett EZ, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-1021
9. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection, United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735-739
10. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006; 173:922-926